Analysis of RhoC expression and lymphovascular emboli in inflammatory vs non-inflammatory breast cancers in Egyptian patients

Breast

Volumn 18, Issue 1, 2009, Pages 55-59

  Lo, An Chi ^a   Georgopoulos, Ageliki ^a   Kleer, Celina G ^b   Banerjee, Mousumi ^a   Omar, Sherif ^c   Khaled, Hussein ^c   Eissa, Saad ^c   Hablas, Ahmed ^d   Omar, Hoda G ^e   Douglas, Julie A ^b   Merajver, Sofia D ^b   Soliman, Amr S ^a  

^a UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c CAIRO UNIVERSITY   (Egypt)

^d Gharbia Cancer Society   (Egypt)

^e Tanta Cancer Center   (Egypt)

Author keywords

Developing countries; Egypt; Inflammatory breast cancer; RhoC; Tumor emboli

Indexed keywords

RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOC GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; EGYPT; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; LYMPH VESSEL; PARITY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR EMBOLISM;

EID: 59849106355     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.breast.2008.11.002     Document Type: Article

References (20)

1. Chang S., Parker S.L., Pham T., Buzdar A.U., and Hursting S.D. Inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program of the National Cancer Institute, 1975-1992. Cancer 82 (1998) 2366-2372
2. Merajver S.D., Goodman V.L., and Sabel M.S. Inflammatory breast cancer: advances in molecular genetics and treatment. In: Bonadonna G., Hortobagyi G.N., and Valagussa P. (Eds). Textbook of breast cancer: a clinical guide to therapy. 3 ed. (2006), Taylor & Francis, London 241-256
3. In: Greene F.L., Page D.L., and Fleming I.D. (Eds). AJCC cancer staging manual. 6 ed. (2002), Springer-Verlag, New York 225-226
4. Anderson W.F., Schairer C., Chen B.E., Hance K.W., and Levine P.H. Epidemiology of inflammatory breast cancer (IBC). Breast Dis 22 (2005-2006) 9-23
5. Kleer C.G., van Golen K.L., and Merajver S.D. Molecular biology of breast cancer metastasis. Inflammatory breast cancer: clinical syndrome and molecular determinants. Breast Cancer Res 2 (2000) 423-429
6. Ridley A.J. Rho proteins and cancer. Breast Cancer Res Treat 84 (2004) 13-19
7. van Golen K.L., Davies S., Wu Z.F., Wang Y., Bucana C.D., Root H., et al. A novel putative low-affinity insulin-like growth factor-binding protein, LIBC (lost in inflammatory breast cancer), and RhoC GTPase correlate with the inflammatory breast cancer phenotype. Clin Cancer Res 5 (1999) 2511-2519
8. Wu M., Wu Z.F., Kumar-Sinha C., Chinnaiyan A., and Merajver S.D. RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat 84 (2004) 3-12
9. Hance K.W., Anderson W.F., Devesa S.S., Young H.A., and Levine P.H. Trends in inflammatory breast carcinoma incidence and survival: the surveillance, epidemiology, and end results program at the National Cancer Institute. J Natl Cancer Inst 97 (2005) 966-975
10. Omar S., and Khaled H. Inflammatory breast cancer. The Newsletter of the International Network for Cancer Treatment and Research 3 (2002) 1-3 (Letter)
11. Lo A.C., Kleer C.G., Banerjee M., Omar S., Khaled H., Eissa S., et al. Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients. Breast Cancer Res Treat 112 (2008) 141-147
12. Kleer C.G., van Golen K.L., Zhang Y., Wu Z.F., Rubin M.A., and Merajver S.D. Characterization of RhoC expression in benign and malignant breast disease: a potential new marker for small breast carcinomas with metastatic ability. Am J Pathol 160 (2002) 579-584
13. Kleer C.G., Griffith K.A., Sabel M.S., Gallagher G., van Golen K.L., Wu Z.F., et al. RhoC-GTPase is a novel tissue biomarker associated with biologically aggressive carcinomas of the breast. Breast Cancer Res Treat 93 (2005) 101-110
14. World Health Organization. Physical status: the use and interpretation of anthropometry (1995), World Health Organization, Geneva, Switzerland: WHO Technical Report Series
15. Lê M.G., Arriagada R., Bahi J., Pfeiffer F., Cammoun M., Tabbane F., et al. Are risk factors for breast cancer similar in women with inflammatory breast cancer and in those with non-inflammatory breast cancer?. Breast 15 (2006) 355-362
16. Chang S., Buzdar A.U., and Hursting S.D. Inflammatory breast cancer and body mass index. J Clin Oncol 16 (1998) 3731-3735
17. Chang S., Alderfer J.R., Asmar L., and Buzdar A.U. Inflammatory breast cancer survival: the role of obesity and menopausal status at diagnosis. Breast Cancer Res Treat 64 (2000) 157-163
18. Levine P.H., Pogo B.G., Klouj A., Coronel S., Woodson K., Melana S.M., et al. Increasing evidence for a human breast carcinoma virus with geographic differences. Cancer 101 (2004) 721-726
19. Soliman A.S., Wang X., DiGiovanni J., Eissa S., Morad M., Vulimiri S., et al. Serum organochlorine levels and history of lactation in Egypt. Environ Res 92 (2003) 110-117
20. Soliman A.S., Vulimiri S.V., Kleiner H.E., Shen J., Eissa S., Morad M., et al. High levels of oxidative DNA damage in lymphocyte DNA of premenopausal breast cancer patients from Egypt. Int J Environ Health Res 14 (2004) 121-134